Vibrent Smartphone Mobile Application

NCT ID: NCT02421536

Last Updated: 2023-01-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-14

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research is being done to evaluate whether or not a customized version of the VibrentTM (formerly FitNinjaTM) mobile app is a feasible way to help people manage and control the pain from radiation sores (also referred to as "mucositis") when treating head and neck cancers with radiation. The mobile app will be designed to help people better understand the pain from the radiation sores and how to better use their medications especially when they are away from the hospital.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed study will evaluate the feasibility of the VibrentTM smartphone application to evaluate radiation-induced mucositis pain "out of the clinic" and it's ability to enhance adherence to the prophylactic pain management algorithm. Successful completion of the proposed study will provide the foundation upon which a randomized trial can be conducted evaluating the efficacy of prophylactic gabapentin / narcotics for various toxicity, patient-reported and oncologic outcomes in patients receiving head and neck radiotherapy. Moreover, successful establishment of this pain analgesic approach may have future implications in other pain models where there is planned neuropathic tissue injury.

Vibrent Management has established a policy and procedure regarding the Privacy of Protected Health Information (PHI) and Security of Electronic Protected Health Information (EPHI). This procedure applies to applicable Vibrent employees and contractors associated with the management of VibrentTM customer's Protected Health Information. VibrentTM products are HIPAA and HITECH Act compliant, and use the highest quality processes based on ISO13485 standard during software design and development. VibrentTM quality process has successfully passed quality audits from leaders in medical devices and pharmaceutical products. The security, privacy, quality processes and HIPAA compliance of VibrentTM LHS (Learning Healthcare System) Cloud hosted system has been cleared for commercial use by the DoD (US Army) to provide remote care management services for soldiers and civilians. In addition, this secure and HIPAA compliant VibrentTM LHS has received SSAE16 certification to prove operational controls needed to ensure such compliance.

The Vibrent LHS security components include security of data in flight and data at rest throughout end-to-end system architecture. VibrentTM mobile and web applications are designed to be secure in handling information provided and stored within it. All data exchanges between mobile applications or web browsers and the website are encrypted. Once a complete patient consult is transmitted from the mobile device and the server acknowledges receipt, all data and photos would be removed automatically from the mobile device. Data stored in the mobile application as well as the website is secured and encrypted. Data is exchanged over the internet securely using HTTPS/SSL.

The VibrentTM server has also been securely integrated with the Johns Hopkins Oncospace® analytic database server allowing secure one-way secure transmission of "out of clinic" assessment data to the "in clinic" Oncospace® analytic database which captures all treatment-related information including all radiotherapy dosimetry information and "in clinic" treatment toxicities and oncologic and toxicity outcome measures including patient-reported outcomes. Integration is particularly important as the radiotherapy dose, volume and the location of the upper aerodigestive tract that is irradiated can all affect the level of the pain experienced from radiation-induced mucositis. Oncospace® was developed to handle all continuous data-points in the dose-volume histogram (DVH) which summarizes the radiotherapy delivered to specific structures delineated in a radiotherapy plan as a series of analyzable relational tables within a database architecture thus facilitating quantification of the radiotherapy treatment and how it may affect radiation-induced mucositis pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mucositis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vibrent Smartphone Application

We propose to pilot the application of the mobile application "VibrentTM" (research procedure) during a course of head and neck radiotherapy for eligible study subjects. Study subjects will be prospective consented and enrolled and will have baseline "out of clinic" assessment with the Vibrent smartphone application (research procedure).

Group Type EXPERIMENTAL

Vibrogent Smartphone Application

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vibrogent Smartphone Application

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Study subjects age ≥ 18 years of age.
2. Study subject with a Karnofsky performance scale of 80 or greater.
3. Study subjects capable of providing informed consent.
4. Study subjects with a previously untreated head and neck cancer diagnosis requiring a definitive or postoperative course of radiotherapy requiring a prescribed dose of radiation therapy
5. Study subjects who have either an Android or Apple iOS-based smartphone or tablet compatible with the VibrentTM software with sufficient monthly data plan (approximately 200 megabytes per month).

Exclusion Criteria

a. No known hypersensitivity or intolerance to gabapentin.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Harry Quon, M.D.

Role: PRINCIPAL_INVESTIGATOR

The SKCCC at Johns Hopkins

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Johns Hopkins Medical Institutions

Baltimore, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB00057815

Identifier Type: OTHER

Identifier Source: secondary_id

J14191

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.